A Phase 4 interventional study of Varenicline 1mg BID and Varenicline 0.5mg BID in Smoking Cessation, sponsored by Pfizer. Completed at 80 sites in 6 countries. Open to participants aged 12 Years to 19 Years. Per ClinicalTrials.gov, last updated 2018-08-09.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 40th largest by enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 55th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 12 Years to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 21st largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 4, and was the 38th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Drug: Varenicline 1mg BID
Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Drug: Varenicline 0.5mg BID
Oral placebo for twelve weeks,follow-up through Week 52
Drug: Placebo
Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Oral placebo for twelve weeks,follow-up through Week 52
4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12
The percentage of participants who, at each visit from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and at each of these visits were confirmed to have quit based on urine cotinine less than 200 nanograms/milliliter (ng/mL).
Time frame: Week 9 through Week 12
Percentage of Participants With 7-Day Point Prevalence of Smoking Abstinence at Weeks 12, 24 and 52
The percentage of participants who reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) on the Nicotine Use Inventory in the 7 days prior to the study visits or telephone contacts at Week 12,24 and 52.
Time frame: Weeks 12, 24 and 52
Daily Number of Cigarettes Smoked at Baseline
The average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.
Time frame: Baseline
Change From Baseline in Daily Number of Cigarettes Smoked at Weeks 12, 24, and 52
The reduction in the number of the cigarettes smoked was calculated by subtracting the reported average number of cigarettes smoked per day in the past 7 days at Weeks 12, 24 and 52 from the average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.
Time frame: Baseline, Weeks 12, 24, and 52
Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52
The percentage of participants who, at each visit from Week 9 to 52 (inclusive), reported no smoking and no use of other nicotine-containing products (Weeks 9-12) or tobacco products (Weeks 13-52) since the last study visit/last contact (on the Nicotine Use Inventory) and at any of the study visits were confirmed to have quit based on urine cotinine less than 200 ng/mL.
Time frame: Week 9 through Week 24; Week 9 through Week 52
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious AEs and SAEs.
Time frame: First dose up to last dose (up-to Week 12) plus 30 days
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug Varenicline was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and SAEs.
Time frame: First dose up to last dose (up-to Week 12) plus 30 days
Number of Participants With Treatment-Emergent Neuropsychiatric Adverse Event Elicited by Neuropsychiatric Adverse Event Interview (NAEI)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE: AE causing: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Solicited AEs collected by semi-structured NAEI inquiring about AEs: depression, anxiety, delusions, hallucinations, paranoia, psychosis, mania, panic, agitation, dissociative states, feeling abnormal, hostility, aggression and homicidal ideation. If a participant had a positive response to any item on the NAEI, investigator determined if it met criteria AE criteria.
Time frame: First dose up to last dose (up-to Week 12) plus 30 days
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories);was an interview-based instrument to systematically assess suicidal ideation and suicidal behavior.C-SSRS assessed whether participant experienced any of the following:completed suicide;suicide attempt(response of "Yes" on "actual attempt");preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior","aborted attempt" or "interrupted attempt"),suicidal ideation ("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act,without specific plan or with specific plan and intent,any self-injurious behavior with no suicidal intent ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").Here,number of participants with positive response (response of "yes") to suicidal behavior or/and Ideation,any non-suicidal self-injurious behavior were reported.
Time frame: Screening, Baseline, Week 1 up to Week 12 (treatment-emergent [TE]), thereafter up to Week 52 (last follow-up [FU])
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A) Total Scores at Specified Time-points
The HADS is a self-administered questionnaire measuring anxiety. Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) consisted of 7 items that were assessed on a scale of 0 = no anxiety to 3 = severe feeling of anxiety. Total HADS-A subscale score range from 0 = no anxiety to 21 = severe anxiety; higher scores indicated more severe anxiety.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores - Depression Total Score at Specified Time-Points
Hospital Anxiety and Depression Scale Depression subscale (HADS-D) consists of 7 items that were assessed on a scale of 0 = no depression to 3 = severe feeling of depression. Total HADS-D subscale score range from 0 = no depression to 21 = severe feeling of depression; higher scores indicated a greater intensity of depression.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 28, 36, 44, and 52
Number of Participants With Laboratory Abnormalities
Criteria for laboratory abnormalities: Lymphocytes Absolute (Abs), Lymphocytes percentage (%), Total Neutrophils (Abs), Neutrophils %: \<0.8\*LLN or \>1.2\*ULN; Basophils (Abs), Basophils %Eosinophils (Abs), Eosinophils %, Monocytes (Abs), Monocytes %:\> 1.2\*ULN; Total Bilirubin milligram per deciliter (mg/dl) \>1.5\*ULN; alanine aminotransferase: \>3.0\*ULN; Blood urea nitrogen, Creatinine: \>1.3\*ULN; Uric acid :\> 1.2\*ULN.
Time frame: Baseline up to Week 12
Change From Baseline in Blood Pressure (BP) at Week 12
Measurement of BP included supine and sitting systolic BP, standing systolic BP, supine and sitting diastolic BP and standing diastolic BP. Blood pressure was taken after participants rested in a sitting position for 5 minutes. BP was recorded after participants had been supine for approximately 5 minutes, and then orthostatic blood pressure was recorded immediately when the participant stood.
Time frame: Baseline, Week 12
Change From Baseline in Pulse Rate at Week 12
Measurement of pulse rate included supine, sitting and standing pulse rate. Pulse rate was taken after participants rested in a sitting position for 5 minutes. Pulse rate was recorded after participants had been supine for approximately 5 minutes and then immediately upon standing.
Time frame: Baseline, Week 12
| Milestone | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Started | 109 | 103 | 100 |
| Treated | 108 | 100 | 99 |
| Completed | 67 | 67 | 53 |
| Not completed | 42 | 36 | 47 |
| Withdrew: Randomized but not treated | 1 | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 2 |
| Withdrew: Other | 9 | 6 | 11 |
| Withdrew: Withdrawal by subject | 8 | 10 | 7 |
| Withdrew: Lost to follow-up | 21 | 17 | 20 |
| Withdrew: Insufficient clinical response | 0 | 0 | 1 |
| Withdrew: Entrance criteria not met | 0 | 0 | 2 |
The percentage of participants who, at each visit from Week 9 through Week 12, reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory) and at each of these visits were confirmed to have quit based on urine cotinine less than 200 nanograms/milliliter (ng/mL).
| percentage of participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 | 20.2 | 27.2 | 18.0 |
The percentage of participants who reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) on the Nicotine Use Inventory in the 7 days prior to the study visits or telephone contacts at Week 12,24 and 52.
| percentage of participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Week 12 | 31.2 | 37.9 | 23.0 |
| Week 24 | 31.2 | 35.9 | 23.0 |
| Week 52 | 28.4 | 35.0 | 20.0 |
The average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.
| cigarettes smoked per day | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Daily Number of Cigarettes Smoked at Baseline | 10.68 ± 0.624 | 9.56 ± 0.530 | 9.57 ± 0.531 |
The reduction in the number of the cigarettes smoked was calculated by subtracting the reported average number of cigarettes smoked per day in the past 7 days at Weeks 12, 24 and 52 from the average number of cigarettes smoked per day in the past 7 days reported at the baseline visit.
| cigarettes smoked per day | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Change at Week 12 | -8.56 ± 0.43 | -8.20 ± 0.44 | -8.01 ± 0.46 |
| Change at Week 24 | -6.93 ± 0.44 | -7.31 ± 0.45 | -6.59 ± 0.48 |
| Change at Week 52 | -6.80 ± 0.45 | -7.74 ± 0.46 | -6.98 ± 0.48 |
The percentage of participants who, at each visit from Week 9 to 52 (inclusive), reported no smoking and no use of other nicotine-containing products (Weeks 9-12) or tobacco products (Weeks 13-52) since the last study visit/last contact (on the Nicotine Use Inventory) and at any of the study visits were confirmed to have quit based on urine cotinine less than 200 ng/mL.
| percentage of participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Week 9 through Week 24 | 10.1 | 24.3 | 13.0 |
| Week 9 through Week 52 | 8.3 | 20.4 | 9.0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious AEs and SAEs.
| Participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 65 | 53 | 52 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug Varenicline was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and SAEs.
| Participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) | 46 | 28 | 27 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE: AE causing: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Solicited AEs collected by semi-structured NAEI inquiring about AEs: depression, anxiety, delusions, hallucinations, paranoia, psychosis, mania, panic, agitation, dissociative states, feeling abnormal, hostility, aggression and homicidal ideation. If a participant had a positive response to any item on the NAEI, investigator determined if it met criteria AE criteria.
| Participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Neuropsychiatric AEs | 18 | 11 | 12 |
| Neuropsychiatric SAEs | 0 | 0 | 0 |
The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) categories);was an interview-based instrument to systematically assess suicidal ideation and suicidal behavior.C-SSRS assessed whether participant experienced any of the following:completed suicide;suicide attempt(response of "Yes" on "actual attempt");preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior","aborted attempt" or "interrupted attempt"),suicidal ideation ("Yes" on "wish to be dead","non-specific active suicidal thoughts","active suicidal ideation with methods without intent to act or some intent to act,without specific plan or with specific plan and intent,any self-injurious behavior with no suicidal intent ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").Here,number of participants with positive response (response of "yes") to suicidal behavior or/and Ideation,any non-suicidal self-injurious behavior were reported.
| Participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Screening:Suicidal Behavior or/and Ideation | 2 | 3 | 2 |
| Screening:Suicidal Ideation | 2 | 3 | 2 |
| Screening: Wish to be Dead | 2 | 2 | 2 |
| Screening: Non-Specific Active Suicidal Thoughts | 1 | 1 | 2 |
| Screen:Self Injurious Behavior, no Suicidal Intent | 3 | 3 | 2 |
| TE:Suicidal Behavior or/and Ideation | 1 | 0 | 1 |
| TE:Suicidal Ideation | 1 | 0 | 1 |
| TE: Wish to be Dead | 1 | 0 | 1 |
| TE: Non-Specific Active Suicidal Thoughts | 0 | 0 | 1 |
| TE:Self Injurious Behavior, no Suicidal Intent | 0 | 0 | 1 |
The HADS is a self-administered questionnaire measuring anxiety. Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) consisted of 7 items that were assessed on a scale of 0 = no anxiety to 3 = severe feeling of anxiety. Total HADS-A subscale score range from 0 = no anxiety to 21 = severe anxiety; higher scores indicated more severe anxiety.
| units on a scale | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Baseline | 2.4 ± 2.05 | 1.9 ± 2.06 | 2.3 ± 2.26 |
| Change at Week 1 | -0.6 ± 1.86 | -0.5 ± 1.53 | -0.3 ± 1.91 |
| Change at Week 2 | -1.1 ± 1.95 | -0.7 ± 1.90 | -0.5 ± 2.18 |
| Change at Week 3 | -1.2 ± 1.85 | -0.8 ± 1.96 | -1.0 ± 2.09 |
| Change at Week 4 | -1.5 ± 1.83 | -0.9 ± 2.31 | -0.9 ± 2.21 |
| Change at Week 5 | -1.3 ± 2.03 | -1.0 ± 2.12 | -1.2 ± 2.19 |
| Change at Week 6 | -1.5 ± 1.91 | -1.0 ± 2.25 | -1.2 ± 2.31 |
| Change at Week 7 | -1.6 ± 2.13 | -1.1 ± 2.41 | -1.2 ± 2.39 |
| Change at Week 8 | -1.5 ± 2.11 | -1.1 ± 2.20 | -1.3 ± 1.99 |
| Change at Week 9 | -1.4 ± 2.17 | -1.2 ± 2.35 | -1.1 ± 2.13 |
| Change at Week 10 | -1.4 ± 2.07 | -1.2 ± 2.44 | -1.1 ± 2.34 |
| Change at Week 11 | -1.4 ± 2.00 | -1.2 ± 2.23 | -1.3 ± 2.12 |
| Change at Week 12 | -1.4 ± 2.07 | -1.3 ± 2.31 | -1.2 ± 2.15 |
| Change at Week 13 | -1.5 ± 2.13 | -1.2 ± 2.17 | -1.2 ± 2.33 |
| Change at Week 14 | -1.4 ± 2.33 | -1.2 ± 2.53 | -1.2 ± 2.19 |
| Change at Week 15 | -1.7 ± 2.09 | -1.3 ± 2.43 | -1.0 ± 3.35 |
| Change at Week 16 | -1.6 ± 2.16 | -1.2 ± 2.44 | -1.1 ± 2.54 |
| Change at Week 20 | -1.5 ± 2.28 | -1.2 ± 2.31 | -1.3 ± 2.21 |
| Change at Week 28 | -1.5 ± 2.54 | -1.2 ± 2.46 | -1.2 ± 2.38 |
| Change at Week 36 | -1.4 ± 2.42 | -1.2 ± 2.51 | -1.3 ± 2.03 |
| Change at Week 44 | -1.8 ± 2.21 | -1.2 ± 2.34 | -1.0 ± 1.90 |
| Change at Week 52 | -1.6 ± 2.20 | -1.1 ± 2.39 | -1.5 ± 2.06 |
Hospital Anxiety and Depression Scale Depression subscale (HADS-D) consists of 7 items that were assessed on a scale of 0 = no depression to 3 = severe feeling of depression. Total HADS-D subscale score range from 0 = no depression to 21 = severe feeling of depression; higher scores indicated a greater intensity of depression.
| units on a scale | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Baseline | 1.5 ± 1.93 | 1.4 ± 1.79 | 1.4 ± 1.83 |
| Change at Week 1 | -0.4 ± 1.43 | -0.2 ± 1.18 | 0.1 ± 1.61 |
| Change at Week 2 | -0.5 ± 1.57 | -0.2 ± 1.65 | -0.1 ± 1.80 |
| Change at Week 3 | -0.5 ± 1.39 | -0.3 ± 1.55 | -0.3 ± 1.79 |
| Change at Week 4 | -0.7 ± 1.39 | -0.3 ± 1.79 | -0.4 ± 2.00 |
| Change at Week 5 | -0.6 ± 1.66 | -0.3 ± 1.97 | -0.3 ± 1.88 |
| Change at Week 6 | -0.6 ± 1.85 | -0.4 ± 1.60 | -0.5 ± 1.83 |
| Change at Week 7 | -0.7 ± 1.52 | -0.5 ± 1.91 | -0.4 ± 2.13 |
| Change at Week 8 | -0.8 ± 1.87 | -0.5 ± 1.80 | -0.5 ± 1.80 |
| Change at Week 9 | -0.8 ± 1.63 | -0.5 ± 1.85 | -0.5 ± 2.30 |
| Change at Week 10 | -0.9 ± 1.67 | -0.7 ± 1.63 | -0.4 ± 2.77 |
| Change at Week 11 | -0.7 ± 1.53 | -0.9 ± 1.66 | -0.5 ± 2.11 |
| Change at Week 12 | -0.7 ± 1.79 | -0.7 ± 1.72 | -0.6 ± 2.11 |
| Change at Week 13 | -0.6 ± 2.16 | -0.7 ± 1.79 | -0.7 ± 1.95 |
| Change at Week 14 | -0.8 ± 1.96 | -0.6 ± 1.84 | -0.5 ± 2.22 |
| Change at Week 15 | -0.8 ± 1.83 | -0.8 ± 1.84 | -0.3 ± 3.26 |
| Change at Week 16 | -0.6 ± 2.09 | -0.6 ± 2.08 | -0.2 ± 2.79 |
| Change at Week 20 | -0.8 ± 1.71 | -0.8 ± 1.84 | -0.6 ± 2.24 |
| Change at Week 28 | -0.9 ± 1.63 | -0.8 ± 1.90 | -0.5 ± 2.40 |
| Change at Week 36 | -0.7 ± 2.19 | -0.8 ± 1.77 | -0.4 ± 2.40 |
| Change at Week 44 | -0.9 ± 1.93 | -0.9 ± 1.78 | -0.3 ± 2.44 |
| Change at Week 52 | -0.7 ± 1.81 | -0.8 ± 1.67 | -0.6 ± 2.02 |
Criteria for laboratory abnormalities: Lymphocytes Absolute (Abs), Lymphocytes percentage (%), Total Neutrophils (Abs), Neutrophils %: \<0.8\*LLN or \>1.2\*ULN; Basophils (Abs), Basophils %Eosinophils (Abs), Eosinophils %, Monocytes (Abs), Monocytes %:\> 1.2\*ULN; Total Bilirubin milligram per deciliter (mg/dl) \>1.5\*ULN; alanine aminotransferase: \>3.0\*ULN; Blood urea nitrogen, Creatinine: \>1.3\*ULN; Uric acid :\> 1.2\*ULN.
| Participants | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 35 | 33 | 26 |
Measurement of BP included supine and sitting systolic BP, standing systolic BP, supine and sitting diastolic BP and standing diastolic BP. Blood pressure was taken after participants rested in a sitting position for 5 minutes. BP was recorded after participants had been supine for approximately 5 minutes, and then orthostatic blood pressure was recorded immediately when the participant stood.
| millimeters of mercury (mmHg) | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Supine Systolic BP:Baseline | 115.0 (85 to 164) | 114.0 (92 to 136) | 109.0 (95 to 142) |
| Supine Systolic BP:Change at Week 12 | 0.0 (-33 to 25) | 0.0 (-32 to 31) | 0.0 (-35 to 43) |
| Sitting Systolic BP:Baseline | 117.0 (90 to 148) | 115.0 (95 to 139) | 113.0 (95 to 135) |
| Sitting Systolic BP:Change at Week 12 | -1.0 (-24 to 31) | 0.0 (-30 to 28) | 2.0 (-28 to 28) |
| Standing Systolic BP:Baseline | 116.0 (88 to 157) | 115.0 (92 to 155) | 112.0 (90 to 136) |
| Standing Systolic BP:Change at Week 12 | 0.0 (-30 to 40) | 0.0 (-21 to 53) | 3.0 (-18 to 47) |
| Supine Diastolic BP:Baseline | 69.0 (45 to 99) | 66.0 (45 to 84) | 65.0 (50 to 90) |
| Supine Diastolic BP:Change at Week 12 | 0.0 (-26 to 17) | 0.0 (-20 to 22) | 0.0 (-35 to 21.0) |
| Sitting Diastolic BP:Baseline | 72.0 (50 to 94) | 70.0 (38 to 92) | 69.0 (47 to 87) |
| Sitting Diastolic BP:Change at Week 12 | 0.0 (-20 to 28) | -1.0 (-35 to 23) | 1.0 (-18 to 22) |
| Standing Diastolic BP:Baseline | 73.0 (57 to 106) | 72.0 (55 to 99) | 70.0 (50 to 92) |
| Standing Diastolic BP:Change at Week 12 | 0.0 (-28 to 22) | -1.0 (-43 to 23) | 2.0 (-21 to 20) |
Measurement of pulse rate included supine, sitting and standing pulse rate. Pulse rate was taken after participants rested in a sitting position for 5 minutes. Pulse rate was recorded after participants had been supine for approximately 5 minutes and then immediately upon standing.
| beats per minute (bpm) | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| Supine Pulse Rate:Baseline | 75.0 (50 to 111) | 72.0 (50 to 105) | 72.0 (54 to 113) |
| Supine Pulse Rate:Change at Week 12 | 0.0 (-32 to 44) | 1.0 (-23 to 23) | 3.0 (-30 to 29) |
| Sitting Pulse Rate:Baseline | 75.0 (58 to 118) | 75.0 (48 to 113) | 77.0 (58 to 115) |
| Sitting Pulse Rate:Change at Week 12 | -1.0 (-22 to 25) | 0.0 (-33 to 30) | 1.0 (-43 to 36) |
| Standing Pulse Rate:Baseline | 84.0 (61 to 139) | 85.0 (61 to 119) | 85.0 (63 to 122) |
| Standing Pulse Rate:Change at Week 12 | 1.0 (-35 to 44) | -3.0 (-25 to 32) | -3.0 (-53 to 44) |
Collected over First dose up to last dose (up-to Week 12) plus 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline High Dose | 0/108 (0%) | 3/108 (2.8%) | 65/108 (60.2%) |
| Varenicline Low Dose | 0/100 (0%) | 1/100 (1%) | 53/100 (53%) |
| Placebo | 0/99 (0%) | 1/99 (1%) | 51/99 (51.5%) |
| Event | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| SalpingitisInfections and infestations | 0/108 | 0/100 | 1/99 |
| Bile duct stoneHepatobiliary disorders | 0/108 | 1/100 | 0/99 |
| Cholecystitis acuteHepatobiliary disorders | 0/108 | 1/100 | 0/99 |
| Campylobacter gastroenteritisInfections and infestations | 1/108 | 0/100 | 0/99 |
| LaryngitisInfections and infestations | 1/108 | 0/100 | 0/99 |
| Adjustment disorder with mixed disturbance of emotion and conductPsychiatric disorders | 1/108 | 0/100 | 0/99 |
| Event | Varenicline High Dose | Varenicline Low Dose | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 26/108 | 19/100 | 12/99 |
| VomitingGastrointestinal disorders | 14/108 | 2/100 | 2/99 |
| HeadacheNervous system disorders | 14/108 | 5/100 | 8/99 |
| AgitationPsychiatric disorders | 9/108 | 5/100 | 5/99 |
| Abnormal dreamsPsychiatric disorders | 8/108 | 5/100 | 4/99 |
| AnxietyPsychiatric disorders | 6/108 | 4/100 | 7/99 |
| DizzinessNervous system disorders | 6/108 | 7/100 | 3/99 |
| HostilityPsychiatric disorders | 7/108 | 3/100 | 4/99 |
| Upper respiratory tract infectionInfections and infestations | 6/108 | 5/100 | 2/99 |
| NasopharyngitisInfections and infestations | 4/108 | 3/100 | 5/99 |
The safety analysis set included all participants who took at least one dose of randomized study medication, including partial doses.
| Age, Continuous(years) | Varenicline High Dose | Varenicline Low Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 16.0 ± 2.0 | 16.0 ± 1.7 | 15.8 ± 1.8 | 15.9 ± 1.8 |
| Sex: Female, Male(Participants) | Varenicline High Dose | Varenicline Low Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 38 | 37 | 36 | 111 |
| Male | 70 | 63 | 63 | 196 |
| Race/Ethnicity, Customized(Participants) | Varenicline High Dose | Varenicline Low Dose | Placebo | Total |
|---|---|---|---|---|
| White | 81 | 73 | 74 | 228 |
| Black | 9 | 9 | 5 | 23 |
| Asian | 16 | 18 | 19 | 53 |
| Other | 2 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2011 to primary completion in Jan 2018, 81 months.
Results were first posted in Jun 2018, 5 months after primary completion.
Of 56 phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's 81 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline